 MICHAEL ANDREEFF
| Title | Professor |
|---|
| Institution | MD Anderson |
|---|
| Department | Leukemia |
|---|
| vCard | Download vCard |
|---|
|
|
|
 ORNG Applications Research F32GM009940 (ANDREEFF, MICHAEL W)Jul 1, 1985 NIH/NIGMS
DIRECTED MUTAGENESIS OF HPRT GENES IN CULTURED CELLS
Role: Principal Investigator |
| R01CA038980 (ANDREEFF, MICHAEL W)Jul 1, 1985 - Dec 31, 1988 NIH/NCI
CELL BIOLOGY AND PHARMACOKINETICS OF LOW-DOSE ARA-C
Role: Principal Investigator |
| R01CA041305 (ANDREEFF, MICHAEL W)Apr 1, 1986 - Mar 31, 1994 NIH/NCI
FUNCTION OF QUIESCENT CELLS IN PEDIATRIC LEUKEMIA
Role: Principal Investigator |
| R29HD022880 (ANDREEFF, MICHAEL W)May 1, 1987 - Apr 30, 1993 NIH/NICHD
MOLECULAR BIOLOGY OF T LYMPHOCYTE PROGENITOR CELLS
Role: Principal Investigator |
| S10RR007383 (ANDREEFF, MICHAEL W)Sep 30, 1991 - Sep 29, 1993 NIH/NCRR
GAMMACELL 40 SELF-CONTAINED IRRADIATOR
Role: Principal Investigator |
| P01CA055164 (ANDREEFF, MICHAEL W)Jun 1, 1992 - Aug 31, 2014 NIH/NCI
THE THERAPY OF AML
Role: Principal Investigator |
| R01CA057639 (ANDREEFF, MICHAEL W)Aug 17, 1992 - Jul 31, 1996 NIH/NCI
CYTOKINE/CHEMOTHERAPY COMBINATIONS IN MYELOID LEUKEMIA
Role: Principal Investigator |
| R01CA062595 (ANDREEFF, MICHAEL W)Sep 1, 1993 - Aug 31, 1997 NIH/NCI
FISH ANALYSIS OF LYMPHOMA
Role: Principal Investigator |
| R01HL051232 (ANDREEFF, MICHAEL W)Aug 1, 1994 - Jul 31, 1998 NIH/NHLBI
GENE TRAP SCREEN APPROACH TO STEM CELL DEVELOPMENT
Role: Principal Investigator |
| R01DK048647 (ANDREEFF, MICHAEL W)Sep 30, 1994 - Aug 31, 1998 NIH/NIDDK
GENETIC ANALYSIS OF STEM CELLS USING DIFFERENTIAL PCR
Role: Principal Investigator |
| R03TW000930 (ANDREEFF, MICHAEL W)May 1, 1998 - Apr 30, 2003 NIH/FIC
BCL2 AND P53 IN CYTO PROTEC OF AML CELLS FROM APOPTOSIS
Role: Principal Investigator |
| R01CA089346 (ANDREEFF, MICHAEL W)Sep 1, 2002 - Aug 31, 2006 NIH/NCI
Anti-Leukemic Activity of the Novel Triterpeniod CDDO
Role: Principal Investigator |
| R01FD003733 (ANDREEFF, MICHAEL W)Sep 21, 2009 - Aug 31, 2014 FDA
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Role: Principal Investigator |
| R21CA143805 (ANDREEFF, MICHAEL W)Apr 5, 2010 - Mar 31, 2014 NIH/NCI
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
Role: Principal Investigator |
| R01FD006118 (ANDREEFF, MICHAEL)Sep 1, 2019 - Jun 30, 2023 FDA
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Role: Principal Investigator |
Bibliographic
-
Forte D, Krause DS, Andreeff M, Bonnet D, Méndez-Ferrer S. Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica. 2019 Oct; 104(10):1928-1934. PMID: 31515356.
-
Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2019 Aug 01. PMID: 31371419.
-
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 Jun 10. PMID: 31237017.
-
Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019 May 24. PMID: 31127149.
-
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2019 May 23. PMID: 31123034.
-
Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019 Jun; 44:126-137. PMID: 31105032.
-
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019 May 13; 35(5):721-737.e9. PMID: 31056398.
-
Kiss T, Bluth T, Braune A, Huhle R, Denz A, Herzog M, Herold J, Vivona L, Millone M, Bergamaschi A, Andreeff M, Scharffenberg M, Wittenstein J, Vidal Melo MF, Koch T, Rocco PRM, Pelosi P, Kotzerke J, Gama de Abreu M. Effects of Positive End-Expiratory Pressure and Spontaneous Breathing Activity on Regional Lung Inflammation in Experimental Acute Respiratory Distress Syndrome. Crit Care Med. 2019 Apr; 47(4):e358-e365. PMID: 30676338.
-
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 Jun 01; 125(11):1855-1866. PMID: 30811597.
-
Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest. 2019 05 01; 129(5):1878-1894. PMID: 30829648.
-
Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-Regulated IL1ß/Cox-2/PGE2/ß-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 Mar 15; 79(6):1165-1177. PMID: 30674535.
-
Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801.
-
Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 May 01; 125(9):1470-1481. PMID: 30500073.
-
Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep. 2018 11 15; 8(1):16837. PMID: 30442990.
-
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139.
-
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776.
-
Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98. PMID: 30341277.
-
Le PM, Andreeff M, Battula VL. Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica. 2018 12; 103(12):1945-1955. PMID: 30337364.
-
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018; 7:26. PMID: 30323983.
-
Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253. PMID: 30051599.
-
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961.
-
Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL. ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway. Mol Cancer Ther. 2018 12; 17(12):2689-2701. PMID: 30237308.
-
Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
-
Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687.
-
Griessinger E, Andreeff M. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. Haematologica. 2018 06; 103(6):921-923. PMID: 29866886.
-
Sanchez M, Xia Z, Rico-Bautista E, Cao X, Cuddy M, Castro DJ, Correa RG, Chen L, Yu J, Bobkov A, Ruvolo V, Andreeff M, Oshima RG, Matsuzawa SI, Reed JC, Zhang XK, Hansel D, Wolf DA, Dawson MI. Oxidized analogs of Di(1H-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity. Oncotarget. 2018 May 18; 9(38):25057-25074. PMID: 29861853.
-
Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver N, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica. 2018 10; 103(10):1642-1653. PMID: 29773601.
-
Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984.
-
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. PMID: 29702001.
-
Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res. 2018 07; 1865(7):959-969. PMID: 29655803.
-
Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, Konopleva M, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica. 2018 05; 103(5):810-821. PMID: 29545342.
-
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146. PMID: 29550383.
-
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res. 2018 05 15; 78(10):2721-2731. PMID: 29490944.
-
Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/ß-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429. PMID: 29463558.
-
Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241. PMID: 29338567.
-
Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R. Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget. 2018 Jan 12; 9(4):4354-4365. PMID: 29435107.
-
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 05; 45(5):824-845. PMID: 29234845.
-
Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M, Andreeff M. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017 Dec 11; 32(6):748-760.e6. PMID: 29232553.
-
Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B. Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget. 2017 Nov 24; 8(60):102150-102160. PMID: 29254232.
-
Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica. 2017 12; 102(12):2048-2057. PMID: 28912176.
-
Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia. 2017 Oct; 19(10):772-780. PMID: 28863346.
-
Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350.
-
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017 Aug 22; 1(19):1546-1550. PMID: 29296796.
-
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717. PMID: 28729302.
-
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
-
Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget. 2017 Oct 13; 8(48):83354-83369. PMID: 29137349.
-
Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight. 2017 Jul 06; 2(13). PMID: 28679949.
-
Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017 09; 102(9):1537-1548. PMID: 28659338.
-
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017 09; 102(9):1519-1529. PMID: 28596283.
-
Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. 2017 Jun 06; 8(23):36936-36949. PMID: 28415808.
-
Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget. 2017 May 23; 8(21):34552-34564. PMID: 28388555.
-
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017 06 15; 129(24):3165-3174. PMID: 28336527.
-
Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ. Combined inhibition of ß-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017 10; 31(10):2065-2074. PMID: 28321124.
-
Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J. 2017 03 10; 7(3):e542. PMID: 28282031.
-
Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, Meng S, Le XF, Andreeff M, Claret FX. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. Clin Cancer Res. 2017 Aug 01; 23(15):4450-4461. PMID: 28270496.
-
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144. PMID: 28270436.
-
Güldner A, Braune A, Ball L, Leme Silva P, Samary C, Insorsi A, Huhle R, Rentzsch I, Becker C, Oehme L, Andreeff M, Vidal Melo MF, Winkler T, Pelosi P, Rieken Macedo Rocco P, Kotzerke J, Gama de Abreu M. The authors reply. Crit Care Med. 2017 03; 45(3):e328-e329. PMID: 28212230.
-
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587. PMID: 28246192.
-
Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017 04; 19(4):445-457. PMID: 28233640.
-
Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep. 2017 02 21; 7:43013. PMID: 28220839.
-
Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017 02 17; 7(2):e527. PMID: 28211885.
-
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337. PMID: 28052408.
-
Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. Blood. 2017 04 06; 129(14):1958-1968. PMID: 28143883.
-
Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M. Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. Cancer Res. 2017 03 15; 77(6):1453-1464. PMID: 28108519.
-
Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. Clin Cancer Res. 2017 07 01; 23(13):3385-3395. PMID: 28096272.
-
Zeng Z, Konopleva M, Andreeff M. Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells. Methods Mol Biol. 2017; 1633:75-86. PMID: 28735481.
-
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274.
-
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440.
-
Carter BZ, Andreeff M. Eradication of CML stem cells. Oncoscience. 2016; 3(11-12):313-315. PMID: 28105453.
-
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
-
Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy. 2017 Jan 02; 13(1):214-215. PMID: 27797294.
-
Cruz CRY, Andreeff M, Barrett J. Editorial. Cytotherapy. 2016 11; 18(11):1349-1350. PMID: 27686830.
-
Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435. PMID: 27657543.
-
Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117. PMID: 27605552.
-
Güldner A, Braune A, Ball L, Silva PL, Samary C, Insorsi A, Huhle R, Rentzsch I, Becker C, Oehme L, Andreeff M, Vidal Melo MF, Winkler T, Pelosi P, Rocco PR, Kotzerke J, Gama de Abreu M. Comparative Effects of Volutrauma and Atelectrauma on Lung Inflammation in Experimental Acute Respiratory Distress Syndrome. Crit Care Med. 2016 09; 44(9):e854-65. PMID: 27035236.
-
Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 12; 91(12):1221-1226. PMID: 27474808.
-
Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097. PMID: 27391151.
-
Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016 10 13; 128(15):1944-1958. PMID: 27540013.
-
Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. 2016 Aug 09; 7(32):51435-51449. PMID: 27283492.
-
Pöppel TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M. [Therapy of bone metastases with radium-223. German guidelines]. Nuklearmedizin. 2016 Sep 26; 55(5):177-86. PMID: 27417067.
-
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
-
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5. PMID: 27169385.
-
Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y, Sweet S, Chevassut T, Andreeff M, Kornblau SM, Li W, Goodell MA. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81. PMID: 27335278.
-
Kojima K, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol. 2016 09; 44(9):791-798. PMID: 27327543.
-
Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016 09 01; 128(9):1260-9. PMID: 27268264.
-
Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016 Jun; 13(2):248-59. PMID: 27458532.
-
Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol. 2016 08; 44(8):740-4. PMID: 27208809.
-
Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1ß signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67. PMID: 26956049.
-
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
-
Han X, Medeiros LJ, Zhang YH, You MJ, Andreeff M, Konopleva M, Bueso-Ramos CE. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S30-8. PMID: 27155969.
-
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016 Feb 16; 9(415):ra17. PMID: 26884599.
-
Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Res. 2016 Mar 15; 76(6):1528-37. PMID: 26822154.
-
Haase R, Andreeff M, Abolmaali N. On the Reliability of Automatic Volume Delineation in Low-Contrast [(18)F]FMISO-PET Imaging. Recent Results Cancer Res. 2016; 198:175-87. PMID: 27318687.
-
Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339.
-
Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis RE, Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta. 2016 Apr; 1863(4):562-71. PMID: 26704388.
-
Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. PMID: 26603259.
-
Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2. PMID: 26752456.
-
Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci. 2015 Dec; 106(12):1705-13. PMID: 26450753.
-
Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Fujimura T, Ikegami T, Nakanaga K, Matsumoto H, Ueno T, Aoki J, Yokomizo T, Konopleva M, Andreeff M, Miida T, Iwabuchi K, Sasai K. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells. Int J Radiat Biol. 2016; 92(1):24-34. PMID: 26809544.
-
Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One. 2015; 10(11):e0139851. PMID: 26556047.
-
Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99. PMID: 26431162.
-
Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2016 Feb 15; 22(4):868-76. PMID: 26459177.
-
Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS One. 2015; 10(10):e0139254. PMID: 26440941.
-
Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS One. 2015; 10(9):e0138377. PMID: 26375587.
-
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70. PMID: 26299958.
-
Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One. 2015; 10(9):e0137210. PMID: 26340096.
-
Zhang Y, Nowicka A, Solley TN, Wei C, Parikh A, Court L, Burks JK, Andreeff M, Woodward WA, Dadbin A, Kolonin MG, Lu KH, Klopp AH. Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. PLoS One. 2015; 10(8):e0136361. PMID: 26317219.
-
Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3a/ß correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin. 2015 Dec; 4:59-68. PMID: 26674329.
-
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015 Jul 16; 126(3):363-72. PMID: 26045609.
-
Ishizawa J, Kojima K, Hail N, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015 Sep; 153:25-35. PMID: 26048327.
-
Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32. PMID: 26031918.
-
Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells. 2015 Aug; 33(8):2400-15. PMID: 25966666.
-
Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946. PMID: 25867648.
-
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92. PMID: 25778529.
-
Sphyris N, Sarkar TR, Battula VL, Andreeff M, Mani SA. GD2 and GD3 synthase: novel drug targets for cancer therapy. Mol Cell Oncol. 2015 Jul-Sep; 2(3):e975068. PMID: 27308452.
-
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81. PMID: 25530214.
-
Mallampati S, Leng X, Ma H, Zeng J, Li J, Wang H, Lin K, Lu Y, Yang Y, Sun B, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, Cai Z, Fang B, Shen H, Han X, Hirsch-Ginsberg CF, Gao X, Paranjape AN, Mani SA, Clise-Dwyer K, Sun X. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. Blood. 2015 May 07; 125(19):2968-73. PMID: 25712988.
-
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597.
-
Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015 Apr; 87(4):346-56. PMID: 25598437.
-
Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, Majeti R, Strunk D. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 2015 Jan 08; 125(2):249-60. PMID: 25406351.
-
Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, Yan M, Hemachandran S, Pathak S, Zhou XJ, Andreeff M, Mohan C. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis Rheumatol. 2014 Nov; 66(11):3129-39. PMID: 25047252.
-
Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, López C, Barreto A, Cardozo C, Palacios P, Morales L, Duque JE, Carmona JU, Konopleva M, Andreeff M, Samudio I. Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. Cancer Microenviron. 2014 Aug; 7(1-2):79-90. PMID: 25112275.
-
Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015 Jun 04; 34(23):2958-67. PMID: 25109336.
-
Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84. PMID: 25079338.
-
Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014; 1(7):504-9. PMID: 25594052.
-
Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74. PMID: 24942980.
-
Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014 Jul; 105(7):795-801. PMID: 24766216.
-
Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. The protein phosphatase 2A regulatory subunit B55a is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta. 2014 Sep; 1843(9):1969-77. PMID: 24858343.
-
Oehme L, Zöphel K, Golgor E, Andreeff M, Wunderlich G, Brogsitter C, de Abreu MG, Kotzerke J. Quantitative analysis of regional lung ventilation and perfusion PET with (68)Ga-labelled tracers. Nucl Med Commun. 2014 May; 35(5):501-10. PMID: 24509518.
-
Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma. 2014 Dec; 55(12):2822-9. PMID: 24628293.
-
Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54. PMID: 24749672.
-
Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 Jul; 13(7):1848-59. PMID: 24739393.
-
Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502.
-
Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis. 2014 Apr; 19(4):698-707. PMID: 24337870.
-
Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May; 73(5):961-74. PMID: 24619497.
-
Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74. PMID: 24619500.
-
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance. Blood. 2014 Apr 24; 123(17):2691-702. PMID: 24599548.
-
Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014 Apr 10; 123(15):2412-5. PMID: 24596420.
-
Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 2014 Apr; 124(4):1512-24. PMID: 24590286.
-
Güldner A, Braune A, Carvalho N, Beda A, Zeidler S, Wiedemann B, Wunderlich G, Andreeff M, Uhlig C, Spieth PM, Koch T, Pelosi P, Kotzerke J, de Abreu MG. Higher levels of spontaneous breathing induce lung recruitment and reduce global stress/strain in experimental lung injury. Anesthesiology. 2014 Mar; 120(3):673-82. PMID: 24406799.
-
Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795.
-
Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412.
-
Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014 Feb; 106(2):djt440. PMID: 24526787.
-
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116.
-
Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4. PMID: 24033106.
-
Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014 Mar; 93(3):485-492. PMID: 24154679.
-
Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453. PMID: 24223100.
-
Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013 Dec; 12(12):2940-9. PMID: 24092807.
-
Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol. 2014; 131(1):59-69. PMID: 24052005.
-
Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):686-92. PMID: 24035716.
-
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926.
-
Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med (Berl). 2013 Dec; 91(12):1383-97. PMID: 23955073.
-
Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013 Oct 17; 122(16):2864-76. PMID: 23943652.
-
Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res. 2013 Sep 01; 73(17):5347-59. PMID: 23838935.
-
Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M. TGF-ß-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 2013; 8(6):e62785. PMID: 23826077.
-
Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):430-4. PMID: 23763920.
-
Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE, Konopleva M, Andreeff M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013 Jul 18; 122(3):357-66. PMID: 23741006.
-
Russell KC, Tucker HA, Bunnell BA, Andreeff M, Schober W, Gaynor AS, Strickler KL, Lin S, Lacey MR, O'Connor KC. Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Eng Part A. 2013 Oct; 19(19-20):2253-66. PMID: 23611563.
-
Haase MG, Liepe K, Faulhaber D, Wunderlich G, Andreeff M, Jung R, Baretton GB, Fitze G, Kotzerke J. Dose-dependent histological alterations in the rat lung following intravenous application of Re-188-labeled microspheres. Int J Radiat Biol. 2013 Oct; 89(10):863-9. PMID: 23578095.
-
Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9. PMID: 23669290.
-
Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013 Jun; 123(6):2395-407. PMID: 23676502.
-
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521.
-
Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16; 121(20):4166-74. PMID: 23564911.
-
Vélez J, Hail N, Konopleva M, Zeng Z, Kojima K, Samudio I, Andreeff M. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol. 2013; 3:67. PMID: 23565503.
-
Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-66. PMID: 23530930.
-
Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N, Konopleva M, Andreeff M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One. 2013; 8(3):e58426. PMID: 23484027.
-
Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013 Aug; 31(4):1023-34. PMID: 23397500.
-
Shinojima N, Hossain A, Takezaki T, Fueyo J, Gumin J, Gao F, Nwajei F, Marini FC, Andreeff M, Kuratsu J, Lang FF. TGF-ß mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 2013 Apr 01; 73(7):2333-44. PMID: 23365134.
-
Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013 Feb 01; 73(3):1037-45. PMID: 23345162.
-
Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M, Marini FC. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 2013 Jan; 15(1):20-32. PMID: 23260083.
-
Hartmann H, Freudenberg R, Andreeff M, Kotzerke J. [Determination of radioactivity by smartphones]. Nuklearmedizin. 2013; 52(2):64-70. PMID: 23503759.
-
Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, Konopleva M, Andreeff M. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 2013 Jun; 27(6):1358-68. PMID: 23247046.
-
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012 11; 12(11):767-75. PMID: 23051844.
-
Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 01; 329(1):45-58. PMID: 23036488.
-
Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Rohban R, Etchart N, Fruehwirth M, Beham-Schmid C, Andreeff M, Strunk D. Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. PLoS One. 2012; 7(9):e44468. PMID: 22970226.
-
Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012 Dec; 91(12):1861-70. PMID: 22893484.
-
Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70. PMID: 22785211.
-
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89. PMID: 22826565.
-
Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44. PMID: 22691121.
-
Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The organic arsenic derivative GMZ27 induces PML-RARa-independent apoptosis in myeloid leukemia cells. Anticancer Res. 2012 Jul; 32(7):2871-80. PMID: 22753750.
-
Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, Konopleva M, Andreeff M, Lee MH, Yeung SC. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012 Jun 15; 11(12):2314-26. PMID: 22659796.
-
Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62. PMID: 22658895.
-
Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176.
-
Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
-
Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPAR? Ligands on Leukemia. PPAR Res. 2012; 2012:483656. PMID: 22685453.
-
Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012 Jun; 122(6):2066-78. PMID: 22585577.
-
Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood. 2012 May 24; 119(21):4971-80. PMID: 22490334.
-
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl). 2012 Oct; 90(10):1133-44. PMID: 22399013.
-
Andreeff M, Claussnitzer J, Oehme L, Freudenberg R, Kotzerke J. [Measurement of ocular lens ionizing radiation exposure after radioiodine therapy]. Nuklearmedizin. 2012; 51(3):79-83. PMID: 22395665.
-
Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One. 2012; 7(2):e30563. PMID: 22363446.
-
Bernstein SH, Venkatesh S, Li M, Lee J, Lu B, Hilchey SP, Morse KM, Metcalfe HM, Skalska J, Andreeff M, Brookes PS, Suzuki CK. The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives. Blood. 2012 Apr 05; 119(14):3321-9. PMID: 22323447.
-
Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83. PMID: 22275381.
-
Liopo AV, Conjusteau A, Konopleva M, Andreeff M, Oraevsky AA. Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles. Nano Biomed Eng. 2012; 4(2):66-75. PMID: 22720194.
-
Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012 Feb 01; 18(3):771-82. PMID: 22167410.
-
Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012 Apr; 26(4):778-87. PMID: 22064351.
-
Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012 Apr; 26(4):788-94. PMID: 22033489.
-
Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636.
-
Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012 May; 26(5):883-92. PMID: 22005789.
-
Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene. 2012 Jun 07; 31(23):2849-61. PMID: 21986948.
-
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 2012 Mar; 26(3):443-50. PMID: 21904380.
-
Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1a-mediated down-regulation of CXCL12. Blood. 2011 Oct 20; 118(16):4431-9. PMID: 21868571.
-
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108. PMID: 21853076.
-
Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7. PMID: 21767516.
-
Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer. 2012 Feb 15; 118(4):1023-31. PMID: 21761401.
-
Abel EL, Bubel JD, Simper MS, Powell L, McClellan SA, Andreeff M, MacLeod MC, DiGiovanni J. Protection against 2-chloroethyl ethyl sulfide (CEES)-induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway. Toxicol Appl Pharmacol. 2011 Sep 01; 255(2):176-83. PMID: 21723306.
-
Liepe K, Faulhaber D, Wunderlich G, Andreeff M, Haase M, Jung R, Oehme L, Dörr W, Kotzerke J. Radiation pneumopathy in the rat after intravenous application of (188)Re-labeled microspheres. Int J Radiat Oncol Biol Phys. 2011 Oct 01; 81(2):529-36. PMID: 21665378.
-
Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011 Nov; 25(11):1711-7. PMID: 21660042.
-
Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012 Jan 05; 31(1):68-79. PMID: 21643014.
-
Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M. Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem. 2011 Jun; 112(6):1696-707. PMID: 21360576.
-
Rakheja D, Konoplev S, Su M, Wheeler D, Muzny DM, Ruvolo VR, Collins R, Karandikar NJ, Andreeff M, Medeiros LJ, Chen W. High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei. Br J Haematol. 2011 Oct; 155(1):125-8. PMID: 21480859.
-
Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer. 2011 Oct 15; 117(20):4696-706. PMID: 21455993.
-
Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95. PMID: 21456010.
-
Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011 Jan; 29(1):11-9. PMID: 21280155.
-
Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74. PMID: 20938744.
-
Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer. 2011 Jan 04; 104(1):91-100. PMID: 21139584.
-
Kotzerke J, Andreeff M, Wunderlich G, Wiggermann P, Zöphel K. [Ventilation-perfusion-lungscintigraphy using PET and 68Ga-labeled radiopharmaceuticals]. Nuklearmedizin. 2010; 49(6):203-8. PMID: 21057723.
-
Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7. PMID: 21041716.
-
Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem. 2010 Dec 24; 285(52):40581-92. PMID: 20956520.
-
Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8. PMID: 20952518.
-
Dasgupta SK, Argaiz ER, Mercado JE, Maul HO, Garza J, Enriquez AB, Abdel-Monem H, Prakasam A, Andreeff M, Thiagarajan P. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010 Oct; 50(10):2167-75. PMID: 20456701.
-
Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol. 2010 Oct; 47(4):362-70. PMID: 20875553.
-
Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, Marini F, Andreeff M, Lang FF. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery. 2010 Sep; 67(3):711-20. PMID: 20651630.
-
Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M, Marini FC. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010 Sep; 12(5):615-25. PMID: 20230221.
-
Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010 Sep; 9(9):2545-57. PMID: 20736344.
-
Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One. 2010 Aug 16; 5(8):e12180. PMID: 20808935.
-
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21. PMID: 20708153.
-
Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010 Aug; 28(8):1435-45. PMID: 20572012.
-
Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9. PMID: 20660823.
-
Fiegl M, Samudio I, Mnjoyan Z, Korchin B, Fritsche H, Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia. 2010 Jul; 24(7):1364-7. PMID: 20508615.
-
Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res. 2010 Jun 15; 70(12):4949-60. PMID: 20501850.
-
Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, Andreeff M, Safe S. Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol. 2010 Aug; 78(2):226-36. PMID: 20488920.
-
Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res. 2010 Jun 01; 70(11):4709-18. PMID: 20484037.
-
Thompson T, Andreeff M, Studzinski GP, Vassilev LT. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther. 2010 May; 9(5):1158-68. PMID: 20406950.
-
Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang RY, Zhang W, Yuan X, Lu H, Caldwell L, Andreeff M. Mesenchymal Stem Cells Overexpressing IFN-ß Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron. 2010 Mar 19; 3(1):83-95. PMID: 21209776.
-
Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, McQueen TJ, Hung MC, Andreeff M. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res. 2010 Mar 15; 70(6):2424-34. PMID: 20215498.
-
Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254.
-
Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, Lang FF. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010 Jan; 66(1):144-56; discussion 156-7. PMID: 20023545.
-
Samudio I, Konopleva M, Carter B, Andreeff M. Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res. 2010; 145:197-217. PMID: 20306253.
-
Kotzerke J, Andreeff M, Wunderlich G. PET aerosol lung scintigraphy using Galligas. Eur J Nucl Med Mol Imaging. 2010 Jan; 37(1):175-7. PMID: 19915837.
-
Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010 Jan; 120(1):142-56. PMID: 20038799.
-
Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106. PMID: 19922650.
-
Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009 Dec 01; 69(23):8932-40. PMID: 19920199.
-
Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14. PMID: 19897582.
-
Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 2010 Apr; 17(4):289-97. PMID: 19876078.
-
Andreeff M, Sommer D, Freudenberg R, Reichelt U, Henniger J, Kotzerke J. [BeO-OSL detectors for dose measurements in cell cultures]. Nuklearmedizin. 2009; 48(6):227-32. PMID: 19862463.
-
Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009 Dec 17; 114(26):5331-41. PMID: 19850741.
-
Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia. 2010 Jan; 24(1):33-43. PMID: 19946262.
-
Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009 Oct; 27(10):2614-23. PMID: 19650040.
-
Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16. PMID: 19723894.
-
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6. PMID: 19652057.
-
Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, Eisenhofer G, Kotzerke J. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin. 2009; 48(5):201-7. PMID: 19639164.
-
Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009 Aug-Oct; 12(4-5):103-13. PMID: 19632887.
-
Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62. PMID: 19458629.
-
Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009; 4(4):e4992. PMID: 19352430.
-
Freudenberg R, Andreeff M, Oehme L, Kotzerke J. [Dosimetry of cell-monolayers in multiwell plates]. Nuklearmedizin. 2009; 48(3):120-6. PMID: 19322501.
-
Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009 Jun; 100(6):1128-36. PMID: 19385969.
-
Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009 Mar 15; 69(6):2163-6. PMID: 19258498.
-
Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia. 2009 Apr; 23(4):784-90. PMID: 19225536.
-
Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009 Feb 15; 15(4):1326-34. PMID: 19228734.
-
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009 Jun 18; 113(25):6411-8. PMID: 19211935.
-
Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 Dec 15; 14(24):8295-301. PMID: 19088047.
-
Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008 Dec; 49(12):2246-55. PMID: 19052971.
-
Zuderman L, Liepe K, Zöphel K, Andreeff M, Kotzerke J, Luboldt W. Radiosynoviorthesis (RSO): influencing factors and therapy monitoring. Ann Nucl Med. 2008 Nov; 22(9):735-41. PMID: 19039551.
-
Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle. 2008 Nov 01; 7(21):3362-70. PMID: 18948750.
-
Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009 Feb 12; 113(7):1504-12. PMID: 18957686.
-
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009 Jun 11; 113(24):6215-24. PMID: 18955566.
-
Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood. 2009 Jan 01; 113(1):154-64. PMID: 18840713.
-
Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008 Nov; 22(11):2041-7. PMID: 18668134.
-
Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008 Oct 01; 112(7):2886-95. PMID: 18633130.
-
Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res. 2008 Jul 01; 68(13):5198-205. PMID: 18593920.
-
Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008 Sep; 22(9):1728-36. PMID: 18548093.
-
Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff M, Konopleva M. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol. 2008 Jun; 142(2):192-201. PMID: 18492113.
-
Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res. 2008 May 15; 14(10):3011-21. PMID: 18483366.
-
Elsawa SF, Novak AJ, Grote D, Konopleva M, Andreeff M, Witzig TE, Ansell SM. CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia. Leuk Res. 2008 Dec; 32(12):1895-902. PMID: 18468679.
-
Wunderlich G, Hartmann H, Andreeff M, Kotzerke J. A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications. Appl Radiat Isot. 2008 Dec; 66(12):1876-80. PMID: 18524608.
-
Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K, Kondo S, Andreeff M, Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1130-9. PMID: 18483301.
-
Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20. PMID: 18451169.
-
Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol. 2008 Jun; 87(5):507-515. PMID: 18415656.
-
Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008 May; 15(10):730-8. PMID: 18401438.
-
Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 2008 Jun; 22(6):1095-105. PMID: 18323801.
-
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98. PMID: 18230792.
-
Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr; 22(4):808-18. PMID: 18200035.
-
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008 Mar 15; 111(6):3183-9. PMID: 18187662.
-
Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008 Apr 01; 111(7):3742-50. PMID: 18187663.
-
Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy. 2008; 10(7):657-67. PMID: 18985472.
-
Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008 Jan; 7(1):48-58. PMID: 18202009.
-
Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007 Dec 15; 67(24):11687-95. PMID: 18089798.
-
Kong G, Wang D, Wang H, Wu J, Bielawski J, Konopleva M, Andreeff M, Ruvolo PP, Maurer BJ. Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia. 2008 Jun; 22(6):1258-62. PMID: 18033322.
-
Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2008 Jan; 140(2):181-90. PMID: 18028486.
-
Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther. 2007 Dec; 6(12):1967-77. PMID: 18075297.
-
Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705. PMID: 17671235.
-
Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol. 2007 Jul; 86(1):8-16. PMID: 17675260.
-
Kress CL, Konopleva M, Martínez-García V, Krajewska M, Lefebvre S, Hyer ML, McQueen T, Andreeff M, Reed JC, Zapata JM. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One. 2007 Jun 27; 2(6):e559. PMID: 17593960.
-
Konopleva M, Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets. 2007 Jun; 8(6):685-701. PMID: 17584025.
-
Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007 Jun 01; 13(11):3380-7. PMID: 17545546.
-
Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007 Jun; 13(6):730-5. PMID: 17515897.
-
Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007 Sep; 14(9):1667-77. PMID: 17510658.
-
Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res. 2007 May 01; 67(9):4210-8. PMID: 17483332.
-
Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ. 2007 Aug; 14(8):1443-56. PMID: 17464329.
-
Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 2007 Apr 01; 67(7):3210-9. PMID: 17409429.
-
Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007 Apr; 48(4):774-85. PMID: 17454637.
-
Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007 Mar 15; 109(6):1152-6. PMID: 17315232.
-
Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2007 Jun 15; 109(12):5473-6. PMID: 17351113.
-
Sun K, Li M, Konopleva M, Konoplev S, Stephens LC, Kornblau SM, Frolova O, Wilkins DE, Ma W, Welniak LA, Andreeff M, Murphy WJ. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant. 2007 May; 13(5):521-9. PMID: 17448911.
-
Brookes PS, Morse K, Ray D, Tompkins A, Young SM, Hilchey S, Salim S, Konopleva M, Andreeff M, Phipps R, Bernstein SH. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res. 2007 Feb 15; 67(4):1793-802. PMID: 17308122.
-
Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, Croce CM. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007 Jun 14; 26(28):4148-57. PMID: 17260024.
-
Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007 Jan 15; 67(2):684-94. PMID: 17234779.
-
Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol. 2007; (180):263-83. PMID: 17554513.
-
Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007 Apr 15; 109(8):3509-12. PMID: 17179228.
-
Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006 Dec; 5(23):2778-86. PMID: 17172851.
-
Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006 Dec; 5(12):3113-21. PMID: 17172414.
-
Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 Dec; 5(23):2769-77. PMID: 17172852.
-
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov; 10(5):375-88. PMID: 17097560.
-
Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):852-9. PMID: 17011457.
-
Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9. PMID: 17077328.
-
Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006 Oct; 5(10):2512-21. PMID: 17041095.
-
Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9. PMID: 16969080.
-
Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73. PMID: 16951235.
-
Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene. 2007 Mar 01; 26(10):1439-48. PMID: 16936778.
-
Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77. PMID: 16882944.
-
Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol. 2006 Oct; 85(10):689-704. PMID: 16832676.
-
Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006 Oct 01; 108(7):2358-65. PMID: 16763210.
-
Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun; 47(6):1062-8. PMID: 16840198.
-
Hail N, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis. 2006 Jun; 11(6):889-904. PMID: 16547589.
-
Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia. 2006 Jul; 20(7):1316-9. PMID: 16642043.
-
Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46. PMID: 16585200.
-
Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006 Apr; 20(4):610-9. PMID: 16482209.
-
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7. PMID: 16556893.
-
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A. 2006 Mar 28; 103(13):5078-83. PMID: 16549775.
-
Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene. 2006 Jul 27; 25(32):4483-90. PMID: 16547503.
-
Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):993-1000. PMID: 16543464.
-
Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006 Mar 15; 12(6):1828-38. PMID: 16551868.
-
Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22. PMID: 16478631.
-
Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2006 Feb; 5(2):317-28. PMID: 16505105.
-
Inoue S, Shanker M, Miyahara R, Gopalan B, Patel S, Oida Y, Branch CD, Munshi A, Meyn RE, Andreeff M, Tanaka F, Mhashilkar AM, Chada S, Ramesh R. MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther. 2006 Feb; 6(1):73-91. PMID: 16475947.
-
Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Contractor R, Andreeff M. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol. 2006 Apr; 69(4):1182-93. PMID: 16410408.
-
Samudio I, Konopleva M, Safe S, McQueen T, Andreeff M. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther. 2005 Dec; 4(12):1982-92. PMID: 16373713.
-
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603.
-
Okcu MF, Wang RY, Bueso-Ramos C, Schober W, Weidner D, Andrassy R, Blakely M, Russell H, Ozkan A, Kuttesch J, Andreeff M, Chan KW, Ater J. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatr Blood Cancer. 2005 Nov; 45(6):787-95. PMID: 15929127.
-
Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia. 2005 Nov; 19(11):1977-84. PMID: 16151469.
-
Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res. 2005 Nov 01; 65(21):9962-70. PMID: 16267021.
-
Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 Feb 15; 107(4):1555-63. PMID: 16254145.
-
Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 2006 Feb 15; 107(4):1546-54. PMID: 16223781.
-
Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23. PMID: 16203783.
-
Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, Sebolt-Leopold J, Konopleva M, Andreeff M. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005 Sep; 19(9):1543-9. PMID: 16001087.
-
Samudio I, Konopleva M, Hail N, Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem. 2005 Oct 28; 280(43):36273-82. PMID: 16118208.
-
Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol. 2005 Aug; 130(4):501-10. PMID: 16098063.
-
Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia. 2005 Aug; 19(8):1350-4. PMID: 15931262.
-
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
-
Liepe K, Andreeff M, Wunderlich G, Kotzerke J. Radiation protection in radiosynovectomy of the knee. Health Phys. 2005 Aug; 89(2):151-4. PMID: 16010126.
-
Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005 Nov 01; 106(9):3150-9. PMID: 16014563.
-
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005 Apr 15; 65(8):3307-18. PMID: 15833864.
-
Wolf D, Rumpold H, Koeck R, Gunsilius E. Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2005 Apr 06; 97(7):540-1; author reply 541-2. PMID: 15812081.
-
Takada Y, Andreeff M, Aggarwal BB. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood. 2005 Jul 15; 106(2):641-9. PMID: 15811958.
-
Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005 Apr 01; 65(7):2890-8. PMID: 15805291.
-
Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol. 2005 Jul; 68(1):119-28. PMID: 15798084.
-
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88. PMID: 15767648.
-
Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, Schuh AC, Wells RA, Messner H, Chun K, Reed JC, Schimmer AD. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005 May 15; 105(10):4043-50. PMID: 15687241.
-
Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, Tafuri A, Andreeff M. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005; 11(21):2779-95. PMID: 16101455.
-
Andreeff M, Wunderlich G, Behge K, Schönmuth T, Kotzerke J. [beta-Radiation exposure with (188)Re-labelled pharmaceuticals]. Nuklearmedizin. 2005; 44(3):94-8. PMID: 15968417.
-
Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42. PMID: 15684699.
-
Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004 Nov 03; 96(21):1593-603. PMID: 15523088.
-
Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 01; 64(21):7927-35. PMID: 15520199.
-
Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004 Oct; 3(10):1249-62. PMID: 15486192.
-
Monaco G, Belmont JW, Konopleva M, Andreeff M, Tavor S, Petit I, Kollet O, Lapidot T. Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. Cancer Res. 2004 Sep 15; 64(18):6832 author reply 6832-3. PMID: 15375005.
-
Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M, Meyn RE. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther. 2004 Aug; 3(8):985-92. PMID: 15299081.
-
Chen JS, Konopleva M, Andreeff M, Multani AS, Pathak S, Mehta K. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol. 2004 Aug; 200(2):223-34. PMID: 15174092.
-
Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol. 2004 Aug; 123(2):380-7. PMID: 15245439.
-
Tabe Y, Konopleva M, Igari J, Andreeff M. Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex. Rinsho Byori. 2004 Aug; 52(8):642-8. PMID: 15478619.
-
Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004 Jun 15; 100(12):2583-91. PMID: 15197800.
-
Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17. PMID: 15131024.
-
Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol. 2004 Apr; 93(1):149-54. PMID: 15047229.
-
Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer. 2004 Apr 01; 100(7):1459-71. PMID: 15042680.
-
Tacke F, Marini FC, Zhao S, McQueen T, Konopleva M, Ruvolo PP, Hu SX, Xu HJ, Andreeff M. Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization. Cancer Biol Ther. 2004 Mar; 3(3):340-7. PMID: 14726688.
-
Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA, Wulf GG. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9. PMID: 14687625.
-
Jiffar T, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M, Andreeff M, Ruvolo PP. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia. 2004 Mar; 18(3):505-12. PMID: 14737078.
-
Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75. PMID: 14628071.
-
Hail N, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). J Biol Chem. 2004 Mar 19; 279(12):11179-87. PMID: 14711815.
-
Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol. 2004; 83 Suppl 1:S51-3. PMID: 15124670.
-
Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE, Korbling M, Estey E, Belmont J, Andreeff M. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells. 2004; 22(2):188-201. PMID: 14990858.
-
Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood. 2004 Mar 01; 103(5):1815-22. PMID: 14630813.
-
Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia. 2003 Nov; 17(11):2122-9. PMID: 12931220.
-
Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003 Nov; 17(11):2081-9. PMID: 12970762.
-
Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407. PMID: 14551133.
-
Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res. 2003 Oct 01; 9(12):4570-7. PMID: 14555532.
-
Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T, Andreeff M. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 2003 Sep 15; 63(18):5926-39. PMID: 14522919.
-
Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, Barry MA. Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7. PMID: 14500347.
-
Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle. 2003 Sep-Oct; 2(5):488-93. PMID: 12963850.
-
O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003 Sep 01; 98(5):888-93. PMID: 12942553.
-
Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec 01; 102(12):4179-86. PMID: 12920030.
-
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8. PMID: 12879469.
-
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003 Jul 15; 63(14):4174-80. PMID: 12874023.
-
Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica. 2003 Jul; 88(7):733-6. PMID: 12857550.
-
Milella M, Kornblau SM, Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):160-90. PMID: 14763161.
-
Liepe K, Andreeff M, Mielcarek J, Barth I, Wunderlich G, Kropp J, Kotzerke J. [Beta-radiation exposure at the finger tips during the radionuclide synovectomy]. Nuklearmedizin. 2003 Jun; 42(3):104-8. PMID: 12802473.
-
Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59. PMID: 12718765.
-
Eksioglu-Demiralp E, Kitada S, Carson D, Garland J, Andreef M, Reed JC. A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis. J Immunol Methods. 2003 Apr 01; 275(1-2):41-56. PMID: 12667669.
-
Schimmer AD, Pedersen IM, Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim Y, Suh WS, Reed JC. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res. 2003 Mar 15; 63(6):1242-8. PMID: 12649183.
-
Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 01; 97(5):1234-41. PMID: 12599230.
-
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5. PMID: 12522009.
-
Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res. 2002 Dec 15; 62(24):7264-72. PMID: 12499268.
-
Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia. 2002 Dec; 16(12):2447-53. PMID: 12454751.
-
Marini FC, Shayakhmetov D, Gharwan H, Lieber A, Andreeff M. Advances in gene transfer into haematopoietic stem cells by adenoviral vectors. Expert Opin Biol Ther. 2002 Dec; 2(8):847-56. PMID: 12517264.
-
Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15; 100(8):2965-72. PMID: 12351409.
-
Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002 Oct; 1(12):989-97. PMID: 12481421.
-
Ueno NT, Anagnostopoulos A, Rondón G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002 Oct; 119(1):131-4. PMID: 12358917.
-
Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002 Sep; 16(9):1713-24. PMID: 12200686.
-
Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002 Aug; 118(2):521-34. PMID: 12139741.
-
Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002 Sep; 50(3):237-42. PMID: 12203106.
-
Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. Blood. 2002 Dec 15; 100(13):4594-601. PMID: 12393637.
-
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002 Jul 01; 62(13):3603-8. PMID: 12097260.
-
Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clin Cancer Res. 2002 Jul; 8(7):2123-33. PMID: 12114412.
-
Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr Opin Hematol. 2002 Jul; 9(4):294-302. PMID: 12042703.
-
Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87. PMID: 12114418.
-
Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9. PMID: 12007503.
-
Tacke F, Trautwein C, Zhao S, Andreeff M, Manns MP, Ganser A, Schöffski P. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver. 2002 Jun; 22(3):205-12. PMID: 12100570.
-
Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4. PMID: 11964319.
-
O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32. PMID: 11932905.
-
Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. PMID: 12153163.
-
Lin H, Guo JQ, Andreeff M, Arlinghaus RB. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia. 2002 Feb; 16(2):294-7. PMID: 11840298.
-
Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002 Feb 01; 20(3):656-64. PMID: 11821445.
-
Clodi K, Asgari Z, Younes M, Palmer JL, Cabanillas F, Carbone A, Andreeff M, Younes A. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer. 2002 Jan 01; 94(1):1-5. PMID: 11815953.
-
Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 2002 Jan; 9(1):30-7. PMID: 11850720.
-
Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002 Jan 01; 99(1):326-35. PMID: 11756188.
-
Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. Cancer Treat Res. 2002; 112:237-62. PMID: 12481719.
-
Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, Richkind K, Paskulin G, Andreeff M, Brizard A, McGavran L, Gemmill RM, Berger R, Drabkin HA. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia. 2001 Sep; 15(9):1408-14. PMID: 11516101.
-
Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001 Sep; 108(6):851-9. PMID: 11560954.
-
Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73. PMID: 11493466.
-
Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
-
Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72. PMID: 11391574.
-
Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001 May 01; 97(9):2784-90. PMID: 11313272.
-
Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood. 2001 May 01; 97(9):2791-7. PMID: 11313273.
-
Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, Rill D, Hurwitz R, Marini F, Andreeff M, Brenner MK. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70. PMID: 11426465.
-
Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol. 2001 Mar; 112(3):749-59. PMID: 11260080.
-
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
-
Moreb JS, Zucali J. Human A1 expression in acute myeloid leukemia and its relationship to Bcl-2 expression. Blood. 2001 Jan 15; 97(2):578-9. PMID: 11202429.
-
Körbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, Fischer H, Andreeff M, McMannis J, Champlin R. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher. 2001; 16(2):82-7. PMID: 11746533.
-
Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000 Jul 15; 96(2):393-7. PMID: 10887097.
-
Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000 Jun 15; 95(12):3929-38. PMID: 10845930.
-
Marini FC, Yu Q, Wickham T, Kovesdi I, Andreeff M. Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther. 2000 Jun; 7(6):816-25. PMID: 10880011.
-
Clodi K, Kliche KO, Zhao S, Weidner D, Schenk T, Consoli U, Jiang S, Snell V, Andreeff M. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. Cytometry. 2000 May 01; 40(1):19-25. PMID: 10754513.
-
Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May; 6(5):1796-803. PMID: 10815900.
-
Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
-
Liu Y, Kleine HD, Engel H, Andreeff M. Cytokine expression of T cells in chronic myeloid leukemia. Chin Med J (Engl). 2000 Mar; 113(3):232-5. PMID: 11775253.
-
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 Feb; 18(3):547-61. PMID: 10653870.
-
Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
-
Konopleva M, Rissling I, Andreeff M. CD38 in hematopoietic malignancies. Chem Immunol. 2000; 75:189-206. PMID: 10851785.
-
Wunderlich G, Pinkert J, Andreeff M, Stintz M, Knapp FF, Kropp J, Franke WG. Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy. Appl Radiat Isot. 2000 Jan; 52(1):63-8. PMID: 10670924.
-
Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92. PMID: 10557066.
-
Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999 Sep; 106(4):995-1004. PMID: 10520003.
-
Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep; 17(9):2819-30. PMID: 10561358.
-
Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol. 1999 Sep; 106(3):827-32. PMID: 10468881.
-
Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
-
O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999 Jun 15; 93(12):4149-53. PMID: 10361112.
-
Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol. 1999 Jun; 111(6):733-40. PMID: 10361507.
-
Aboul-Nasr R, Estey EH, Kantarjian HM, Freireich EJ, Andreeff M, Johnson BJ, Albitar M. Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol. 1999 Jun; 111(6):753-8. PMID: 10361510.
-
Marini FC, Snell V, Yu Q, Zhang X, Singletary SE, Champlin R, Andreeff M. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Clin Cancer Res. 1999 Jun; 5(6):1557-68. PMID: 10389945.
-
Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84. PMID: 10194425.
-
Engel H, Drach J, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Goodacre A, Andreeff M. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia. 1999 Apr; 13(4):568-77. PMID: 10214863.
-
Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40. PMID: 10370786.
-
Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999 Mar 01; 93(5):1668-76. PMID: 10029596.
-
Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E, Andreeff M, Champlin RE. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999 Jan 15; 67(1):124-30. PMID: 9921808.
-
Ruan S, Okcu MF, Pong RC, Andreeff M, Levin V, Hsieh JT, Zhang W. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res. 1999 Jan; 5(1):197-202. PMID: 9918219.
-
Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Jan; 32(3-4):279-88. PMID: 10037025.
-
Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999 Jan; 17(1):284-92. PMID: 10458244.
-
Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36. PMID: 10500797.
-
Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998 Dec 01; 92(11):4220-9. PMID: 9834227.
-
Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
-
Munker R, Zhao S, Jiang S, Snell V, Andreeff M, Andersson BS. Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leuk Res. 1998 Nov; 22(11):1073-7. PMID: 9783811.
-
Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol. 1998 Nov 01; 161(9):4702-8. PMID: 9794400.
-
Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2717-21. PMID: 9829734.
-
Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol. 1998 Oct; 103(1):217-9. PMID: 9792311.
-
Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol. 1998 Oct; 103(1):270-5. PMID: 9792321.
-
Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res. 1998 Aug; 4(8):1971-6. PMID: 9717827.
-
Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res. 1998 Aug; 4(8):1955-63. PMID: 9717825.
-
Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ. 1998 Jul; 5(7):584-91. PMID: 10200513.
-
Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):666-74. PMID: 9593263.
-
Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res. 1998 Apr 01; 58(7):1538-43. PMID: 9537261.
-
Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M, Zhang W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene. 1998 Mar 26; 16(12):1587-91. PMID: 9569026.
-
Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer. 1998 Mar 16; 75(6):925-32. PMID: 9506539.
-
DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med. 1998 Mar; 104(3):246-51. PMID: 9552087.
-
Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med. 1998 Mar; 4(3):158-64. PMID: 9562974.
-
Lee HY, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J Clin Invest. 1998 Mar 01; 101(5):1012-9. PMID: 9486971.
-
Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood. 1998 Mar 01; 91(5):1742-8. PMID: 9473241.
-
Wang MW, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth AB. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ. 1998 Feb; 9(2):105-12. PMID: 9486846.
-
Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol. 1998; 99(2):106-8. PMID: 9554461.
-
Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol. 1998 Jan; 100(1):135-41. PMID: 9450802.
-
Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma. 1998 Jan; 28(3-4):371-5. PMID: 9517508.
-
Andreeff M, Kropp J, Beuthien-Baumann B, Oehme L, Hliscs R, Schellong S, Prescher Y, Franke WG, Daniel WG. [Equipment for modification of nuclear medicine lung diagnosis as triggered SPECT--presentation, phantom studies and clinical value]. Biomed Tech (Berl). 1998; 43 Suppl:76-7. PMID: 9859265.
-
Schmitt T, Oehme L, Andreeff M, Foe Owono GD, Franke WG, Freyer R. [3D segmenting method for volume quantification of ECT (emission-computed tomography) data]. Biomed Tech (Berl). 1998; 43 Suppl:70-1. PMID: 9859262.
-
Foe Owono GD, Schmitt T, Oehme L, Andreeff M, Franke WG, Freyer R. [Effect of corrective procedures on volume quantification of SPECT data]. Biomed Tech (Berl). 1998; 43 Suppl:470-1. PMID: 9859447.
-
Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997 Dec; 99(3):618-24. PMID: 9401075.
-
Consoli U, Van NT, Neamati N, Mahadevia R, Beran M, Zhao S, Andreeff M. Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia. 1997 Dec; 11(12):2066-74. PMID: 9447822.
-
Munker R, Younes A, Cabanillas F, Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma. 1997 Nov; 27(5-6):517-21. PMID: 9477134.
-
Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F, Andreeff M. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol. 1997 Nov; 15(11):3355-62. PMID: 9363866.
-
Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood. 1997 Nov 01; 90(9):3673-81. PMID: 9345052.
-
Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol. 1997 Oct; 99(1):64-75. PMID: 9359505.
-
Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, Deisseroth AB. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst. 1997 Sep 03; 89(17):1271-6. PMID: 9293917.
-
Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes M, Cabanillas F, Andreeff M. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol. 1997 Sep; 98(4):913-21. PMID: 9326189.
-
Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia. 1997 Aug; 11(8):1386-90. PMID: 9264399.
-
Consoli U, Li H, Huang P, Kobayashi T, Andreeff M, Levin V, Zhang W. Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline. Oncol Rep. 1997 Jul-Aug; 4(4):673-8. PMID: 21590120.
-
Konishi H, Steinbach G, Terry NH, Fujita K, Lee JJ, Ruifrok A, Spaulding D, Lynch PM, Dubin JA, Andreeff M, Goodacre AM, Hattori T, Hittelman WN. S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. Cancer Epidemiol Biomarkers Prev. 1997 Jul; 6(7):531-6. PMID: 9232341.
-
Kobayashi T, Clodi K, Yang Y, Ruan S, Shiku H, Andreeff M, Shay J, Zhang W. Inhibition of telomerase activity correlates with a decrease in the RNA component of telomerase during differentiation. Int J Oncol. 1997 Jul; 11(1):13-7. PMID: 21528174.
-
Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, Lewis V, Mirza NQ, Andreeff M, Koller C, Elting L, Bodey GP, Whimbey E. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997 Jun; 24(6):1095-9. PMID: 9195063.
-
Mehta K, McQueen T, Manshouri T, Andreeff M, Collins S, Albitar M. Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood. 1997 May 15; 89(10):3607-14. PMID: 9160665.
-
Rondón G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma. 1997 May; 25(5-6):463-7. PMID: 9250816.
-
Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997 May; 15(5):1796-802. PMID: 9164187.
-
Munker R, Marini F, Jiang S, Savary C, Owen-Schaub L, Andreeff M. Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing. Hematol Cell Ther. 1997 Apr; 39(2):75-8. PMID: 9168303.
-
Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer. 1997 Mar 28; 71(1):35-41. PMID: 9096663.
-
Nowak R, Oelschlaegel U, Schuler U, Zengler H, Hofmann R, Ehninger G, Andreeff M. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry. 1997 Feb 15; 30(1):47-53. PMID: 9056742.
-
Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997 Feb 15; 89(4):1133-42. PMID: 9028934.
-
Younes A, Zhao S, Zhang X, Snell V, Clodi K, Kliche KO, Thomas E, Cabanillas F, Andreeff M. CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol. 1997; 8 Suppl 2:97-100. PMID: 9209650.
-
Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51. PMID: 8986814.
-
Konishi H, Steinbach G, Hittelman WN, Fujita K, Lee JJ, Glober GA, Levin B, Andreeff M, Goodacre AM, Terry NH. Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. Gastroenterology. 1996 Dec; 111(6):1493-500. PMID: 8942727.
-
Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996 Nov 15; 88(10):3987-97. PMID: 8916965.
-
Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996 Oct 01; 88(7):2473-9. PMID: 8839838.
-
Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9. PMID: 8847890.
-
Tari AM, Andreeff M, Kleine HD, Lopez-Berestein G. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med (Berl). 1996 Oct; 74(10):623-8. PMID: 8912183.
-
Zhao S, Consoli U, Arceci R, Pfeifer J, Dalton WS, Andreeff M. Semi-automated PCR method for quantitating MDR1 expression. Biotechniques. 1996 Oct; 21(4):726-31. PMID: 8891227.
-
Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood. 1996 Sep 15; 88(6):2201-9. PMID: 8822940.
-
Munker R, Midis G, Owen-Schaub L, Andreff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia. 1996 Sep; 10(9):1531-3. PMID: 8751476.
-
Munker R, Andreeff M. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther. 1996 Sep; 2(3):147-59. PMID: 9384699.
-
Rondón G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996 Sep; 18(3):669-72. PMID: 8879640.
-
Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood. 1996 Sep 01; 88(5):1747-54. PMID: 8781431.
-
Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood. 1996 Jul 15; 88(2):633-44. PMID: 8695811.
-
Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996 Jul 01; 56(13):3010-20. PMID: 8674056.
-
Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, Cabanillas F, Andreeff M. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol. 1996 Jun; 93(3):569-71. PMID: 8652374.
-
Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE, Shay JW. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res. 1996 May; 2(5):799-803. PMID: 9816233.
-
Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996 Mar; 21(1-2):85-92. PMID: 8907274.
-
Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Cabanillas F, Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood. 1996 Mar 01; 87(5):1698-703. PMID: 8634414.
-
Escudier SM, Albitar M, Robertson LE, Andreeff M, Pierce S, Kantarjian HM. Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia. 1996 Mar; 10(3):473-7. PMID: 8642864.
-
Mehta K, McQueen T, Neamati N, Collins S, Andreeff M. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ. 1996 Feb; 7(2):179-86. PMID: 8822201.
-
Jiang S, Munker R, Andreeff M. Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. Nat Immun. 1996-1997; 15(6):312-7. PMID: 9523282.
-
Kobayashi T, Consoli U, Andreeff M, Shiku H, Deisseroth AB, Zhang W. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene. 1995 Dec 07; 11(11):2311-6. PMID: 8570182.
-
Preti HA, Huh YO, O'Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995 Nov 01; 76(9):1564-70. PMID: 8635059.
-
O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995 Nov 01; 86(9):3322-6. PMID: 7579434.
-
Jakubowski A, Gordon M, Tafuri A, Schuster S, Andreeff M, Shieh JH, Vincent M, Gabrilove J. A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia. Leukemia. 1995 Nov; 9(11):1799-804. PMID: 7475265.
-
Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995 Nov; 13(11):2827-34. PMID: 7595745.
-
Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia. 1995 Oct; 9(10):1735-41. PMID: 7564518.
-
Körbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8. PMID: 7545476.
-
Del Giglio A, Drach J, Kornblau SM, Patel S, Novaes M, Khetan R, Sawaya N, Dorlhiac-Llacer P, Chamone DF, Andreeff M, et al. Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma. 1995 Oct; 19(3-4):235-41. PMID: 8535214.
-
Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DE. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995 Sep 15; 86(6):2098-105. PMID: 7662957.
-
Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9. PMID: 7658710.
-
Estey E, Andreeff M. Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia. 1995 Sep; 9(9):1440-3. PMID: 7658709.
-
Tafuri A, de Felice L, Goodacre A, Fenu S, Petrucci MT, Valentini T, Alimena G, Petti MC, Meloni G, Mandelli F, et al. Interleukin-3 priming in acute myeloid leukaemia patients. Br J Haematol. 1995 Sep; 91(1):234-44. PMID: 7577641.
-
Hegewisch-Becker S, Hanania EG, Fu S, Körbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol. 1995 Aug; 90(4):876-83. PMID: 7669666.
-
Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995 Aug; 21(2):376-9. PMID: 8562747.
-
Younes A, Jendiroba D, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. Cancer Genet Cytogenet. 1995 Jul 01; 82(1):23-9. PMID: 7627930.
-
Jendiroba D, Younes A, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia. 1995 Jul; 9(7):1144-6. PMID: 7630187.
-
Chang KS, Fan YH, Andreeff M, Liu J, Mu ZM. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood. 1995 Jun 15; 85(12):3646-53. PMID: 7780148.
-
Drach D, Zhao S, Drach J, Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br J Haematol. 1995 Jun; 90(2):369-74. PMID: 7794759.
-
Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T, et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther. 1995 Jun; 2(4):285-94. PMID: 7552989.
-
Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5. PMID: 7596181.
-
Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res. 1995 Jun; 1(6):583-90. PMID: 9816019.
-
Younes A, Zhao S, Jendiroba D, Kleine HD, Cabanillas F, Andreeff M. Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood. 1995 May 15; 85(10):2813-6. PMID: 7742542.
-
Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer. 1995 May; 3(3):198-202. PMID: 7655781.
-
Wetzler M, Talpaz M, Yee G, Stass SA, Van Etten RA, Andreeff M, Goodacre AM, Kleine HD, Mahadevia RK, Kurzrock R. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3488-92. PMID: 7724587.
-
Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65. PMID: 7888684.
-
Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther. 1995 Mar; 1(1):21-8. PMID: 9384660.
-
Drach J, Zhao S, Drach D, Körbling M, Engel H, Andreeff M. Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma. 1995 Feb; 16(5-6):419-24. PMID: 7540457.
-
Zhang W, Xu HJ, Kornblau SM, Drach J, Hu SX, Andreeff M, Benedict WF, Deisseroth AB. Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk Lymphoma. 1995 Jan; 16(3-4):191-8. PMID: 7719226.
-
Nguyen D, Diamond LW, Cherubino P, Koala WB, Imbert M, Andreeff M. A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases. Medinfo. 1995; 8 Pt 1:771-5. PMID: 8591323.
-
Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88. PMID: 7535143.
-
Diamond LW, Nguyen DT, Andreeff M, Maiese RL, Braylan RC. A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas. Cytometry. 1994 Nov 01; 17(3):266-73. PMID: 7851162.
-
Younes A, Jendiroba D, Engel H, Escudier S, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. Cancer Genet Cytogenet. 1994 Oct; 77(1):39-44. PMID: 7923081.
-
Anderlini P, Przepiorka D, Luna M, Langford L, Andreeff M, Claxton D, Deisseroth AB. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):459-61. PMID: 7994273.
-
Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):449-53. PMID: 7994271.
-
Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry. 1994 Sep 01; 17(1):84-93. PMID: 8001461.
-
Huh YO, Andreeff M. Flow cytometry. Clinical and research applications in hematologic malignancies. Hematol Oncol Clin North Am. 1994 Aug; 8(4):703-23. PMID: 7961287.
-
Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreeff M. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia. 1994 May; 8(5):749-57. PMID: 7514244.
-
Körbling M, Drach J, Champlin RE, Engel H, Huynh L, Kleine HD, Berenson R, Deisseroth AB, Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant. 1994 May; 13(5):649-54. PMID: 7519938.
-
Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ, Malavasi F, Mehta K. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res. 1994 Apr 01; 54(7):1746-52. PMID: 7511050.
-
San-Miguel JF, Bartram C, Campana D, Andreeff M. Minimal residual disease in hematologic malignancies. Rev Invest Clin. 1994 Apr; Suppl:147-52. PMID: 7886299.
-
Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994 Apr; 12(4):671-8. PMID: 7512125.
-
Younes A, Drach J, Katz R, Jendiroba D, Sabourian MH, Sarris AH, Swan F, Hill D, Cabanillas F, Ford R, et al. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol. 1994 Mar; 5(3):265-8. PMID: 7514436.
-
Younes A, Pugh W, Goodacre A, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer. 1994 Mar; 9(3):161-7. PMID: 7515657.
-
O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994 Feb 03; 330(5):319-22. PMID: 7904047.
-
Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34. PMID: 8186294.
-
Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61. PMID: 7688862.
-
Baccarani M, Damiani D, Michelutti A, Michieli M. Expression of multidrug resistance gene (MDR1) in normal hematopoietic cells. Blood. 1993 Jun 15; 81(12):3480-1. PMID: 8507883.
-
Weiss M, Telford P, Kempin S, Kritz A, Sogoloff H, Gee T, Berman E, Scheinberg D, Little C, Gaynor J, et al. Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Leukemia. 1993 Jun; 7(6):832-7. PMID: 8501978.
-
Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Andreeff M. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood. 1993 May 15; 81(10):2702-7. PMID: 7683927.
-
Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. 1993 May 01; 53(9):2100-4. PMID: 8481912.
-
Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993 Feb; 11(2):294-303. PMID: 8426207.
-
Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
-
Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993; 11 Suppl 2:59-63. PMID: 7510196.
-
Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry. 1993; 14(5):492-6. PMID: 8354121.
-
Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. Cancer Invest. 1993; 11(2):229-34. PMID: 8462024.
-
Przepiorka D, Giralt S, Huh YO, Andreeff M, Luna M, Reading C, Thomas M, Champlin RE. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma. Transplant Proc. 1992 Dec; 24(6):2906-7. PMID: 1465994.
-
Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood. 1992 Dec 01; 80(11):2729-34. PMID: 1360266.
-
Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15; 80(10):2604-9. PMID: 1421378.
-
Claxton DF, Plunkett W, Andreeff M, Deisseroth AB. Retinoids and cancer therapy. J Natl Cancer Inst. 1992 Sep 02; 84(17):1306-7. PMID: 1495098.
-
Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, et al. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res. 1992 Sep 01; 52(17):4587-90. PMID: 1511426.
-
Lichtman SM, Andreeff M. Flow cytometric analysis of cytokinetics of L3-acute lymphoblastic leukemia/lymphoma. Leuk Res. 1992 Sep; 16(9):853-9. PMID: 1405716.
-
Gulati S, Acaba L, Yahalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpodien J, et al. Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant. 1992 Aug; 10(2):129-34. PMID: 1525601.
-
Lemoli RM, Tafuri A, Strife A, Andreeff M, Clarkson BD, Gulati SC. Proliferation of human hematopoietic progenitors in long-term bone marrow cultures in gas-permeable plastic bags is enhanced by colony-stimulating factors. Exp Hematol. 1992 Jun; 20(5):569-75. PMID: 1587303.
-
Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol. 1992 Jun; 20(5):558-64. PMID: 1587302.
-
Zhang W, Hittelman W, Van N, Andreeff M, Deisseroth A. The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle. Biochem Biophys Res Commun. 1992 Apr 15; 184(1):212-6. PMID: 1567429.
-
Zhang W, Drach J, Andreeff M, Deisseroth A. Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70. Biochem Biophys Res Commun. 1992 Mar 16; 183(2):733-8. PMID: 1550580.
-
Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Straus D, Gansbacher B, Filippa D, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992 Mar 01; 79(5):1305-10. PMID: 1536954.
-
Fuks Z, Vlodavsky I, Andreeff M, McLoughlin M, Haimovitz-Friedman A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer. 1992; 28A(4-5):725-31. PMID: 1524892.
-
Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Med Pediatr Oncol Suppl. 1992; 2:18-22. PMID: 1306881.
-
Herrmann F, Andreeff M, Gruss HJ, Brach MA, Lübbert M, Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood. 1991 Oct 15; 78(8):2070-4. PMID: 1912585.
-
Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991 May 16; 324(20):1385-93. PMID: 1850498.
-
Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991 Apr 15; 77(8):1666-74. PMID: 2015395.
-
Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood. 1991 Feb 15; 77(4):700-11. PMID: 1993213.
-
Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 1991 Feb 15; 77(4):818-25. PMID: 1993221.
-
Tafuri A, Meyers J, Lee BJ, Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer. 1991 Jan 15; 67(2):449-54. PMID: 1985738.
-
Crown JP, Jhanwar S, Haimi J, Andreef M, Gee T. Acquired cyclic haematopoiesis associated with a radiation-induced chromosomal abnormality with clonal, morphologically normal circulating leucocytes. Acta Haematol. 1991; 86(2):103-6. PMID: 1950369.
-
Kempin S, Arlin Z, Berman E, Gee T, Mertelsmann R, Andreeff M, Kolitz J, Jhanwar S, Myers J, Clarkson B. Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC). Leuk Lymphoma. 1991; 4(2):111-6. PMID: 27462940.
-
Shalinsky DR, Andreeff M, Howell SB. Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res. 1990 Dec 01; 50(23):7537-43. PMID: 1979245.
-
Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia. 1990 Dec; 4(12):826-34. PMID: 2243506.
-
Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science. 1990 Oct 26; 250(4980):559-62. PMID: 2237408.
-
Bettelheim P, Muhm M, Valent P, Geissler K, Andreeff M, Haimi J, Sillaber C, Hinterberger W, Vieder L, Schulz G, et al. GM-CSF in combination with cytotoxic chemotherapy in AML patients. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:127-30. PMID: 2202464.
-
Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res. 1990 Apr 01; 50(7):2049-55. PMID: 2156611.
-
Clarkson B, Gaynor J, Little C, Berman E, Kempin S, Andreeff M, Gulati S, Cunningham I, Gee T. Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia. Haematol Blood Transfus. 1990; 33:397-408. PMID: 2182430.
-
Redner A, Hegewisch S, Haimi J, Steinherz P, Jhanwar S, Andreeff M. A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia. Leuk Res. 1990; 14(9):771-7. PMID: 2232849.
-
Andreeff M, Tafuri A, Hegewisch-Becker S. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Haematol Blood Transfus. 1990; 33:747-62. PMID: 2323674.
-
Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989 Nov; 4(11):1363-74. PMID: 2682463.
-
Haluska FG, Russo G, Kant J, Andreef M, Croce CM. Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis. Proc Natl Acad Sci U S A. 1989 Nov; 86(22):8907-11. PMID: 2682665.
-
Bartlett WC, Michael A, McCann J, Yuan D, Claassen E, Noelle RJ. Cognate interactions between helper T cells and B cells. II. Dissection of cognate help by using a class II-restricted, antigen-specific, IL-2-dependent helper T cell clone. J Immunol. 1989 Sep 15; 143(6):1745-54. PMID: 2476481.
-
Andreeff M, Welte K. Hematopoietic colony-stimulating factors. Semin Oncol. 1989 Jun; 16(3):211-29. PMID: 2471272.
-
Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia. 1989 Feb; 3(2):115-21. PMID: 2911205.
-
Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol. 1989 Feb; 16(1 Suppl 2):30-4. PMID: 2928808.
-
Arlin ZA, Hagenbeek A, Feldman EJ, Andreeff M. Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased? Acta Haematol. 1989; 82(4):175-8. PMID: 2511718.
-
Berman E, Raymond V, Gee TS, Kempin SJ, Gulati S, Andreeff M, Gabrilove J, Young CW, Clarkson BD, Wiernik PH, et al. Idarubicin in acute leukemia: results of US trials. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:49. PMID: 2713561.
-
Paietta E, Andreeff M, Papenhausen P, Gucalp R, Wiernik PH. Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia. Leukemia. 1989 Jan; 3(1):76-8. PMID: 2909810.
-
Gulati SC, Gaynor J, Esseesse I, Gee T, Little C, Andreeff M, Berman E, Kempin S, Clarkson B. Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC). Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:86-9. PMID: 2653525.
-
Chouaib S, Bensussan A, Termijtelen AM, Andreeff M, Marchiol-Fournigault C, Fradelizi D, Dupont B. Allogeneic T cell activation triggering by MHC class I antigens. J Immunol. 1988 Jul 15; 141(2):423-9. PMID: 2838549.
-
Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, Arlin Z, Berman E, Kempin S, Gee T, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988 Jun; 6(6):1014-30. PMID: 3163722.
-
Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M, et al. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 1988 Mar 01; 48(5):1337-42. PMID: 3342412.
-
Haluska FG, Russo G, Andreeff M, Croce CM. Molecular analysis of an AIDS-associated Burkitt's lymphoma: near-identity with endemic cases. Curr Top Microbiol Immunol. 1988; 141:75-9. PMID: 3215057.
-
Kong XB, Andreeff M, Fanucchi MP, Fox JJ, Watanabe KA, Vidal P, Chou TC. Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. Leuk Res. 1987; 11(11):1031-9. PMID: 3480397.
-
Andreeff M, Gaynor J, Chapman D, Little C, Gee T, Clarkson BD. Prognostic factors in acute lymphoblastic leukemia in adults: the Memorial Hospital experience. Haematol Blood Transfus. 1987; 30:111-24. PMID: 3476352.
-
Andreeff M. Cell kinetics of leukemia. Semin Hematol. 1986 Oct; 23(4):300-14. PMID: 3535084.
-
Ciobanu N, Paietta E, Andreeff M, Papenhausen P, Wiernik PH. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation. Exp Hematol. 1986 Aug; 14(7):626-35. PMID: 3525202.
-
Benedetto P, Mertelsmann R, Szatrowski TH, Andreeff M, Gee T, Arlin Z, Kempin S, Clarkson B. Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. J Clin Oncol. 1986 Apr; 4(4):489-95. PMID: 3958762.
-
Andreeff M, Slater DE, Bressler J, Furth ME. Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines. Blood. 1986 Mar; 67(3):676-81. PMID: 3511984.
-
Redner A, Melamed MR, Andreeff M. Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA. Ann N Y Acad Sci. 1986; 468:241-55. PMID: 2425687.
-
Andreeff M, Hansen H, Cirrincione C, Filippa D, Thaler H. Prognostic value of DNA/RNA flow cytometry of B-cell non-Hodgkin's lymphoma: development of laboratory model and correlation with four taxonomic systems. Ann N Y Acad Sci. 1986; 468:368-86. PMID: 2425690.
-
Redner A, Grabowski E, Al-Katib A, Andreeff M. Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy. Leuk Res. 1986; 10(6):671-6. PMID: 3458978.
-
Andreeff M, Assing G, Cirrincione C. Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis. Ann N Y Acad Sci. 1986; 468:387-406. PMID: 2425691.
-
Koziner B, Stavnezer J, Al-Katib A, Gebhard D, Mittelman A, Andreeff M, Clarkson BD. Surface immunoglobulin light chain expression in pre-B cell leukemias. Ann N Y Acad Sci. 1986; 468:211-26. PMID: 2425686.
-
Clarkson BD, Gee T, Arlin ZA, Mertelsmann R, Kempin SJ, Dinsmore RE, O'Reilly RJ, Andreeff M, Berman E, Little C, et al. Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. Crit Rev Oncol Hematol. 1986; 4(3):221-48. PMID: 3513984.
-
Suarez C, Miller DR, Steinherz PG, Melamed MM, Andreeff M. DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation. Br J Haematol. 1985 Aug; 60(4):677-86. PMID: 3861195.
-
Clarkson B, Ellis S, Little C, Gee T, Arlin Z, Mertelsmann R, Andreeff M, Kempin S, Koziner B, Chaganti R, et al. Acute lymphoblastic leukemia in adults. Semin Oncol. 1985 Jun; 12(2):160-79. PMID: 2409604.
-
Andreeff M, Bressler J, Higgins P. [Oncogens and cancer. Review and a new method for measuring the gene expression in relation to the cell cycle]. Dtsch Med Wochenschr. 1985 Jan 04; 110(1):30-5. PMID: 3855293.
-
Wustrow TP, Andreeff M, Fernandes G, Good RA. DNA and RNA analysis by flow cytometry of the leukemia in AKR mice. Leuk Res. 1985; 9(10):1283-91. PMID: 2415780.
-
Andreeff M, Bartal A, Feit C, Hirshaut Y. Clonal stability and heterogeneity of hybridomas: analysis by multiparameter flow cytometry. Hybridoma. 1985; 4(3):277-87. PMID: 2412947.
-
Sordillo PP, Andreeff M, Helson L, Steinmetz J, Melamed MR. Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol. Cancer Invest. 1985; 3(4):321-5. PMID: 4027754.
-
Redner A, Andreeff M, Miller DR, Steinherz P, Melamed M. Recognition of central nervous system leukemia by flow cytometry. Cytometry. 1984 Nov; 5(6):614-8. PMID: 6596184.
-
Welte K, Andreeff M, Platzer E, Holloway K, Rubin BY, Moore MA, Mertelsmann R. Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med. 1984 Nov 01; 160(5):1390-403. PMID: 6092510.
-
Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet. 1984 Oct; 13(2):181-3. PMID: 6478442.
-
Mintzer DM, Andreeff M, Filippa DA, Jhanwar SC, Chaganti RS, Koziner B. Progression of nodular poorly differentiated lymphocytic lymphoma to Burkitt's-like lymphoma. Blood. 1984 Aug; 64(2):415-21. PMID: 6547626.
-
Blumenreich MS, Woodcock TM, Andreeff M, Hiddemann W, Chou TC, Vale K, O'Hehir M, Clarkson BD, Young CW. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Cancer Res. 1984 May; 44(5):2203-7. PMID: 6713407.
-
Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res. 1984 Feb; 44(2):825-30. PMID: 6692380.
-
Suarez CR, Andreeff M, Miller DR. Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma. Med Pediatr Oncol. 1984; 12(2):89-92. PMID: 6583472.
-
Shank B, Andreeff M, Li D. Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation. Int J Radiat Oncol Biol Phys. 1983 Nov; 9(11):1613-23. PMID: 6358155.
-
Barlogie B, Raber MN, Schumann J, Johnson TS, Drewinko B, Swartzendruber DE, Göhde W, Andreeff M, Freireich EJ. Flow cytometry in clinical cancer research. Cancer Res. 1983 Sep; 43(9):3982-97. PMID: 6347364.
-
Chaganti RS, Jhanwar SC, Arlin Z, Koziner B, Ambati A, Andreeff M, Clarkson BD. Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes. Cancer Genet Cytogenet. 1983 Sep; 10(1):95-103. PMID: 6576853.
-
Dörner MH, Broxmeyer HE, Silverstone A, Andreeff M. Biosynthesis of ferritin subunits from different cell lines of HL-60 human promyelocytic leukaemia cells and the release of acidic isoferritin-inhibitory activity against normal granulocyte-macrophage progenitor cells. Br J Haematol. 1983 Sep; 55(1):47-58. PMID: 6576806.
-
Hiddemann W, Büchner T, Andreeff M, Arlin Z, Wörmann B, Clarkson BD. [Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity]. Onkologie. 1983 Aug; 6(4):179-83. PMID: 6355946.
-
Warrell RP, Krown SE, Koziner B, Andreeff M, Kempin SJ. Acute non-lymphoblastic leukemia after treatment of nodular lymphoma with human leukocyte interferon. Ann Intern Med. 1983 Apr; 98(4):482-3. PMID: 6340577.
-
Feldman SP, Mertelsmann R, Venuta S, Andreeff M, Welte K, Moore MA. Sodium azide enhancement of interleukin-2 production. Blood. 1983 Apr; 61(4):815-8. PMID: 6600947.
-
Ciobanu N, Andreeff M, Safai B, Koziner B, Mertelsmann R. Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma. Ann Intern Med. 1983 Feb; 98(2):151-5. PMID: 6572044.
-
Anger B, Bockman R, Andreeff M, Erlandson R, Jhanwar S, Kameya T, Saigo P, Wright W, Beattie EJ, Oettgen HF, Old LJ. Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer. 1982 Oct 15; 50(8):1518-29. PMID: 7116286.
-
Hiddemann W, Büchner T, Andreeff M, Wörmann B, Melamed MR, Clarkson BD. Cell kinetics in acute leukemia: a critical reevaluation based on new data. Cancer. 1982 Jul 15; 50(2):250-8. PMID: 7083131.
-
Chiao JW, Andreeff M, Freitag WB, Arlin Z. Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells. J Exp Med. 1982 May 01; 155(5):1357-69. PMID: 6175721.
-
Hiddemann W, Clarkson BD, Büchner T, Melamed MR, Andreeff M. Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood. 1982 Feb; 59(2):216-25. PMID: 7055637.
-
Hiddemann W, Büchner T, Andreeff M, Wörmann B, Melamed MR, Clarkson BD. Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material. Leuk Res. 1982; 6(4):601-12. PMID: 6183535.
-
Lu L, Broxmeyer HE, Pelus LM, Andreeff M, Moore MA. Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60. Exp Hematol. 1981 Oct; 9(9):887-92. PMID: 6175532.
-
Melamed DE, Fogh J, Andreeff M. Characterization of cultured human tumor cell lines by flow cytometry DNA stemline. Anal Quant Cytol. 1981 Mar; 3(1):67-72. PMID: 7015945.
-
Darzynkiewicz Z, Andreeff M. Multiparameter flow cytometry. Part I: application in analysis of the cell cycle. Clin Bull. 1981; 11(2):47-57. PMID: 6173142.
-
Chiao JW, Freitag WF, Steinmetz JC, Andreeff M. Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium. Leuk Res. 1981; 5(6):477-89. PMID: 6977076.
-
Andreeff M, Darzynkiewicz Z. Multiparameter flow cytometry. Part II. application in hematology. Clin Bull. 1981; 11(3):120-30. PMID: 6175445.
-
Hiddemann W, Andreeff M, Clarkson BD. Quantitation of chemotherapy-induced cytoreduction in acute leukemia. Haematol Blood Transfus. 1981; 26:73-6. PMID: 7319296.
-
Kaur P, Miller DR, Andreeff M, Chaganti R, Meyers PA. Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature. Med Pediatr Oncol. 1981; 9(1):69-80. PMID: 7007854.
-
Andreeff M, Clarkson BD. [Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment]. Internist (Berl). 1980 Jul; 21(7):371-5. PMID: 7007271.
-
Hellriegel KP, Andreeff M. [Summary: Therapy of chronic myelogenous leukemia--prognosis]. Internist (Berl). 1980 Jul; 21(7):380-1. PMID: 7007273.
-
Koziner B, Mertelsmann R, Andreeff M, Arlin Z, Hansen H, De Harven E, McKenzie S, Gee T, Good RA, Clarkson B. Heterogeneity of cell lineages in L3 leukemias. Blood. 1980 Apr; 55(4):694-8. PMID: 6244017.
-
Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood. 1980 Feb; 55(2):282-93. PMID: 6928106.
-
Beck JD, Andreeff M, Mertelsmann R, Haghbin M, Tan C, Miller DR, Good RA, Gupta S. Childhood CML in blastic stage: an analysis of cell markers and cell kinetics. Am J Hematol. 1980; 9(3):337-44. PMID: 6165242.
-
Barlogie B, Latreille J, Freireich EJ, Fu CT, Mellard D, Meistrich M, Andreeff M. Characterization of hematologic malignancies by flow cytometry. Blood Cells. 1980; 6(4):719-44. PMID: 7008871.
-
Straus DJ, Andreeff M, Hansen HJ, Mertelsmann R, Koziner B, Chaganti R, Gee TS, McKenzie S, Melamed MR, Clarkson BD. The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis. Blood. 1979 Dec; 54(6):1428-33. PMID: 292459.
-
Beck JD, Andreeff M, Haghbin M, Miller D, Good RA, Gupta S. Surface marker analysis and flow cytometric studies of acute nonlymphocytic leukemias in children and young adults. Clin Immunol Immunopathol. 1979 Nov; 14(3):275-83. PMID: 291503.
-
Darzynkiewicz Z, Traganos F, Andreeff M, Sharpless T, Melamed MR. Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells as revealed by flow cytometry. J Histochem Cytochem. 1979 Jan; 27(1):478-85. PMID: 86572.
-
Darzynkiewicz Z, Andreeff M, Traganos F, Sharpless T, Melamed MR. Discrimination of cycling and non-cycling lymphocytes by BUdR-suppressed acridine orange fluorescence in a flow cytometric system. Exp Cell Res. 1978 Aug; 115(1):31-5. PMID: 79494.
-
Andreeff M, Beck JD, Darzynkiewicz Z, Traganos F, Gupta S, Melamed MR, Good RA. RNA content in human lymphocyte subpopulations. Proc Natl Acad Sci U S A. 1978 Apr; 75(4):1938-42. PMID: 306108.
-
Andreeff M, Kuhn E. [Diastolic murmur caused by a phaeochromocytoma (author's transl)]. Dtsch Med Wochenschr. 1975 Jul 18; 100(29):1530-1. PMID: 1149633.
-
Andreeff VM. [Bleomycin effect on DNA replication and proliferation kinetics using Ehrlich ascites tumor as a model]. Arzneimittelforschung. 1975 Apr; 25(4):566-71. PMID: 50846.
-
Andreeff M, Stoffner D, Dayss U, Abenhardt W. [Autoregulatory growth inhibition in experimental tumors]. Verh Dtsch Ges Inn Med. 1975; 81:1615-8. PMID: 1227034.
-
Andreeff M. [Effect of various new cytostatic agents on DNA reduplication and proliferation kinetics in the Ehrlich-Lettre ascites tumor model]. Verh Dtsch Ges Inn Med. 1974; 80:1678-80. PMID: 4454511.
-
Bothmann G, Rummel HH, Andreeff M, Gailus F. [The value of impulse cytophotometry in the examination of ascitic fluid, contents of cysts and secretions from the cul-de-sac]. Geburtshilfe Frauenheilkd. 1973 Jun; 33(6):483-91. PMID: 4730615.
-
Goerttler K, Rummel H, Haag D, Bothmann G, Andreeff M. [Interpretation of differencies in the DNA-values of exfoliated cells in gynecologic smears (author's transl)]. Verh Dtsch Ges Pathol. 1973; 57:217-22. PMID: 4142180.
-
Andreeff M, Mono G, Kohn R, Kuhn E. [Heart involvement in hemochromatosis]. Verh Dtsch Ges Inn Med. 1971; 77:436-8. PMID: 4265150.
-
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology.
-
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports.
-
Detection and quantitation of BCR-ABL transcripts using a comprehensive quantitative rtpcr analysis system for minimal residual disease in CML patients. Blood. 96.
-
Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacology and Therapeutics.
-
Regulatory pathways in programmed cell death. Cancer Molecular Biology. 6:1229-1260.
-
Photo thermal and photoacoustic processes in laser activated nano-thermolysis of cells.
-
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
-
The combinatorial complexity of cancer precision medicine. Oncoscience. 1:504-509.
-
Higher levels of expression of BCL-2 and BCL-XL in poor prognosis monosomy 5 and monosomy 7} acute myeloid leukemia (AML) cells than in good prognosis (inversion 16 and translocation 8;21) aml cells. Journal of Investigative Medicine. 44.
-
Mesenchymal stem/stromal cell-targeted therapies for solid tumors and hematological malignancies. 799-819.
-
Gene therapy. Cancer Bulletin. 45:139-145.
-
Reviews in Clinical and Experimental Hematology. Reviews in Clinical and Experimental Hematology. 7:115-116.
-
The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 Mutations. Cancer Research. 76:1528-1537.
-
Erratum. Cancer Research. 66:5975.
-
Targeting survivin in leukemia. Oncology Reviews. 1:195-204.
-
Differential sensitivity of CD4+ and CD8+ T lymphocytes to phorbol myristate acetate upon anti-CD3 stimulation. International Journal of Immunopathology and Pharmacology. 4:19-32.
-
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget. 7:55083-55097.
-
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 128:971-981.
-
Kinetic and biochemical modulation of pyrimidine antimetabolites in therapy of acute leukemia. 767.
-
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
-
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
-
Reviews in Clinical and Experimental Hematology. Reviews in Clinical and Experimental Hematology. 7:229-230.
-
Dual tel-abl fusion in a PH-negative chronic myeloid leukemia patient. Blood. 96.
-
Convention on nomenclature for DNA cytometry. Cytometry. 5:445-446.
-
GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene.
-
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 8.
-
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia. Cancer Science. 106:1705-1713.
-
Methyl 2-cyano-3,12-dioxooleana-1, 9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth. Molecular Pharmacology. 79:336.
-
Chemotherapy of acute non-lymphocytic leukemia - new cell kinetic determinants. Cell and Tissue Kinetics. 13:685.
-
Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors. 157-175.
-
Differential expression of bcr/abl mRNA as determined by in situ amplification as s marker of disease progression in CMLs. Experimental Hematology. 25:868.
-
Editorial. Cytotherapy. 18:1349-1350.
-
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.
-
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Frontiers in Oncology. 3 APR.
-
Vergleich der therapieeffektivität von zwei induktionsprotokollen bei akuter myeloischer leukämie (AML) mittels exakter quantifizierung der knochenmarkzellularität. Oncology research and treatment. 6:179-183.
-
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy. 13:214-215.
-
MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One. 10.
-
Concise manual of hematology and oncology.
-
Medical and Pediatric Oncology. 20:18-22.
-
LANTCET.
-
Quantitation of therapy induced cytoreduction in acute myeloblastic leukemia (AML). 461.
-
Mesenchymal stem cells (MSC) as carriers of hologically active molecules in cancer and leukemia therapy. European Journal of Cancer. 37.
-
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
-
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.
-
Errata. Blood. 126:1049.
-
Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias. Blood. 96.
-
Erratum. Cancer Cell. 30:183.
-
Proliferation and differentiation of normal and leukemic lymphocytes as analyzed by flow cytometry. 392-397.
-
Preface. Unknown Journal. v-viii.
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29:574-586.
-
Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology. 44:740-744.
-
Comparison of the therapeutic efficacy of two induction regimens for acute myelocytic leukemia (AML) by accurate quantitation of bone marrow cellularity. Blut. 45:219-220.
-
Mesenchymal Stromal Cells. Biology of Blood and Marrow Transplantation. 13:53-57.
-
Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opinion on Investigational Drugs. 8:2027-2057.
-
Eradication of CML stem cells. Oncoscience. 3:313-315.
-
QDot nanocrystals in intracellular flow. 424-427.
-
High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia.
-
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology.
-
New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.
-
Preface. Unknown Journal.
-
Non B- non T acute lymphoblastic leukemia (ALL).
-
Photothermolysis by laser-induced microbubbles generated around gold nanorod clusters selectively formed in leukemia cells.
-
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochimica et Biophysica Acta - Molecular Cell Research. 1863:562-571.
-
Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clinical Cancer Research. 22:868-876.
-
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget. 7:20054-20067.
-
Treatment of Newly-Diagnosed AML with idarubicin + ARA-C. Leukemia and Lymphoma. 7.
-
Targeted therapy of acute myeloid leukemia.
-
Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells. Cancer Microenvironment. 7:79-90.
-
Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells. 33:2400-2415.
-
Correction. PLoS One. 8.
-
FINE NEEDLE ASPIRATION OF BONE MARROW FROM STERNUM. The Lancet. 320:880.
-
Stromal cells derived from visceral and obese adipose tissue promote growth of ovarian cancers. PLoS One. 10.
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
-
Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models. Clinical Cancer Research. 22:1687-1698.
-
Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. 7:51435-51449.
-
Current status of treatment of acute leukemia in adults. Critical Reviews in Oncology and Hematology. 4:221-248.
-
Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (sine) XPO1 antagonist KPT-185. PLoS One. 10.
-
Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 7:74380-74392.
-
Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clinical. 4:59-68.
-
Expression of multidrug resistance (mdr-1) and p53 genes in hematologic cell systems. Cancer Bulletin. 45:131-138.
-
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351)). Proceedings of the National Academy of Sciences of the United States of America. 94:5495.
-
NACHWEIS VON MINIMALER RESTERKRANKUNG BEI PATIENTEN MIT AKUTER MYELOISCHER LEUKAMIE UND MYELODYSPLASTISCHEM SYNDROM IN KLINISCHER REMISSION MITTELS MOLEKULARER ZYTOGENETIK. Laboratoriums Medizin. 21:613-621.
-
Treatment of philadelphia chromosome positive (ph +) chronic myelogenous leukemia in blast crisis and ph + acute leukemia with high dose cytosine arabinoside (HDARAC). Leukemia and Lymphoma. 4:111-116.
-
Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction. PLoS One. 10.
-
Chromatin structure in leukaemia. Cell and Tissue Kinetics. 15:679.
-
Regulation of apoptosis in AMI, MDS and normal hematopoiesis. Experimental Hematology. 24:1128.
-
Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. PLoS One. 10.
-
Photothermal therapy of acute leukemia cells in the near-infrared region using gold nanorods CD-33 conjugates.
-
Pharmacological activation of wild-type p53 in the therapy of leukemia. Experimental Hematology. 44:791-798.
-
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
-
Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia. Cancer Biology and Medicine. 13:248-259.
-
Erratum. Blood. 93:3573.
-
Treatment of Newly-Diagnosed AML with Idarubicin + ARA-C. Leukemia and Lymphoma. 7:121.
-
Reduction de l'alloreactivite des cellules mononucleees. Hematologie. 5:104-107.
-
Clonal stability of hybridoma clones determined by flow cytometry.
-
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A. 87:346-356.
-
Erratum. Gastroenterology. 116:1507.
-
Iap family of proteins as therapeutic targets for acute myeloid leukemia. 151-173.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 1989 | 10 | | 1990 | 8 | | 1991 | 8 | | 1992 | 14 | | 1993 | 11 | | 1994 | 15 | | 1995 | 29 | | 1996 | 21 | | 1997 | 21 | | 1998 | 25 | | 1999 | 18 | | 2000 | 11 | | 2001 | 12 | | 2002 | 25 | | 2003 | 20 | | 2004 | 20 | | 2005 | 24 | | 2006 | 28 | | 2007 | 22 | | 2008 | 26 | | 2009 | 21 | | 2010 | 25 | | 2011 | 21 | | 2012 | 22 | | 2013 | 28 | | 2014 | 24 | | 2015 | 26 | | 2016 | 27 | | 2017 | 31 | | 2018 | 24 | | 2019 | 11 |
To return to the timeline, click here.
|
ANDREEFF's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|